Results 181 to 190 of about 21,108 (240)

First-derivative synchronous spectrofluorimetric method for simultaneous determination of dapagliflozin and sitagliptin in dosage forms and spiked human plasma. [PDF]

Sci Rep
El-Dosoky MA, El-Desouky EA, Abdelzaher AM, Hasan MA, Mahdy MA.   +4 more
europepmc   +1 more source

Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1735-1743, October 2026.
Older age, atrial fibrillation, loop diuretic use, and higher eGFR variability predicted early eGFR dip. Continued SGLT2 inhibitor therapy preserved long‐term kidney function, although closer monitoring is warranted in patients receiving loop diuretics. ABSTRACT Aim To assess the prevalence, risk factors, estimated glomerular filtration rate trajectory,
Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee   +7 more
wiley   +1 more source

Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study. [PDF]

Front Clin Diabetes Healthc
Joshi S, Samajdar SS, Gupta A, Bhartia M, Lodha S, Bhattacharyya S, Seshadri K, Nagendra L, Unnikrishnan AG, Padhye D, Kopalle LN, Das AK, Lakhani O, Kesavadev J, Joshi A, Das S, Gadia S, Anthuvan T.   +17 more
europepmc   +1 more source

Effect of dapagliflozin on mineral homeostasis in patients with type 2 diabetes: A real-world retrospective cohort study. [PDF]

J Taibah Univ Med Sci
Alshammeri T, El Sayed I, Abdelazim D.
europepmc   +1 more source

Localized Multidrug-Resistant <i>Morganella morganii</i> Urinary Tract Infection in a Dapagliflozin-Treated Man with Bladder Outlet Obstruction and Incomplete Ureteral Duplication: A Case Report. [PDF]

Reports (MDPI)
Nicolae C, Munteanu MA, Petca R, Rascu SA, Danau RA.   +4 more
europepmc   +1 more source

Dapagliflozin and cognitive impairment: pharmacological mechanisms, translational evidence, and future directions. [PDF]

Front Pharmacol
Alhowail AH.
europepmc   +1 more source

Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia. [PDF]

J ASEAN Fed Endocr Soc
Alharajin R, AlTaweel M, AlSubaiee M, Al Makhloof S, Almusaad A, Alarfaj A, AlKhayyal A, Altharman N, Alalawi A, Almannai N, Alohaymid M, Alsaad A, Alotaibi T, Alkhaldi R, Almoaibed G, Alrashada J, Alarfaj A, Alqarni T, Alshahrani A, Aldossary I, Khashwayn S, Al Qarni A, Taleb Y, Alshaikh Husain M.   +23 more
europepmc   +1 more source

Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis. [PDF]

Lancet Reg Health Am
Araujo JS, Moioni F, Novielli DS, Jelusic GA, Lucini SI, Zabalo JA, Spala JA, Piervincenzi MC.   +7 more
europepmc   +1 more source

Dapagliflozin Augmentation of Sacubitril/Valsartan Therapy in Patients With Heart Failure Following PCI-Treated Acute Myocardial Infarction: A Meta-Analysis of Clinical Efficacy and Safety. [PDF]

Cardiol Res Pract
Tang T, Yu H, Zhang Y, Li S, Guo M.
europepmc   +1 more source